1,464 results on '"Moliterno, David"'
Search Results
152. The Use of Drug-Eluting Stents Versus Bypass Surgery for Left Main Coronary Artery Disease
153. Contemporary occurrence of stent thrombosis in clinical practice: Better never than late
154. Creating Biodegradable-Polymer Drug-Eluting Stents: Shortening the Duration of Polymer and Dual Antiplatelet Therapy While Lengthening the Follow-Up‡
155. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
156. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
157. Rescue Coronary Intervention for Failed Thrombolysis
158. Emerging Treatment of Acute Coronary Syndromes with Platelet Glycoprotein IIB/IIIA Inhibitors
159. Restenosis and in-stent restenosis
160. Contributors
161. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
162. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: pooled analysis from EPIC, EPILOG, and EPISTENT
163. A Randomized Two-by-Two Comparison of High-Dose Bolus Tirofiban Versus Abciximab and Unfractionated Heparin Versus Bivalirudin During Percutaneous Coronary Revascularization and Stent Placement: The Tirofiban Evaluation of Novel Dosing versus Abciximab with Clopidogrel and Inhibition of Thrombin (TENACITY) Study Trial
164. Patient, Heal Thyself: The Ongoing Evolution of Patient Self-directed Care and Hand-Held Technology
165. Unfractionated Versus Low-Molecular-Weight Heparin for Primary Angioplasty—More Data Suggesting to Go Low
166. Improving the Design of Future PCI Trials for Stable Coronary Artery Disease
167. Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine
168. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study
169. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study
170. Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials
171. Editorial: Protein C and S Deficiency as a Risk Factor for Stent Thrombosis—When a Rare Disorder Can Predispose to Rare Events
172. Rotational Atherectomy for Resistant Chronic Total Occlusions: Another Spin for Tough Old Problems
173. Ticagrelor with or without Aspirin in High-Risk Patients after PCI
174. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
175. Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes
176. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry
177. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
178. Bedside activated partial thromboplastin time monitoring: just a matter of time?
179. Left main and multivessel coronary artery stenting for patients deemed inoperable—A real need for a tandem approach
180. Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention
181. Trifurcation left main coronary artery percutaneous revascularization—Pushing catheters and envelopes
182. Are we appropriately triaging patients with unstable angina?
183. TIMI flow and surrogate end points: what you see is not always what you get
184. Advances in Antiplatelet Therapy for ACS and PCI
185. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
186. Late drug-eluting stent thrombosis in unprotected left main coronary artery lesions—sometimes possible, but rarely definite or probable
187. Racial Differences in Outcome Following Percutaneous Coronary Intervention
188. Late Percutaneous Recanalization of Totally Occluded Infarct-Related Arteries—More Than About Time
189. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study
190. Late Target Lesion Revascularization Following Drug-Eluting Stents—Looking Back and Forward to Success
191. Effectiveness of Drug-Eluting Stents in Real-World Patients
192. Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy
193. Mitral Regurgitation and Evolving Transcatheter Treatments: Insights From the JACC Family of Journals
194. The authors’ reply
195. Restenosis Following Thin-Strut Bare-Metal Stents Versus Thick-Strut Drug-Eluting Stents
196. The Challenge of Quantifying Exceedingly Rare Occurrences: We Can Only See What We See
197. Thrombus Predicts Ischemic Complications During Percutaneous Coronary Intervention in Saphenous Vein Grafts: Results From Target (Do Tirofiban and Reopro Give Similar Efficacy Trial?)
198. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups
199. The Timely Coupling of Mechanical Revascularization following Thrombolysis for Myocardial Infarction
200. Randomized, placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.